Global Dry Eye Disease Market

Dry Eye Disease Comprehensive Study by Type (Artificial Tears, Anti-inflammatory Drugs, Punctal Plugs, Secretagogue), Application (Hospital Pharmacies, Independent Pharmacies & Drug Stores, Online Pharmacies), Anti-inflammatory Drugs (Cyclosporine, Corticosteroids, Lifitegrast) Players and Region - Global Market Outlook to 2029

Dry Eye Disease Market by XX Submarkets | Forecast Years 2024-2029 | CAGR: 4.35%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Dry eye syndrome (DES) is also called as keratisis sicca and keratoconjunctivitis sicca. The symptoms of DES are ocular surface, instability in the tear film, and optical trouble. That can potentially damage to ocular surface. With increasing Prevalence of the eye diseases and lack of treatment availability, the market will show enormous opportunities.

AttributesDetails
Study Period2019-2029
Base Year2023
High Growth MarketAsia Pacific
UnitValue (USD Million)
Key Companies ProfiledSanten Pharmaceutical Co., Ltd. (Japan), Novartis AG (Switzerland), Johnson & Johnson (United States), Valeant Pharmaceuticals International, Inc. (Canada), Allergan plc (Ireland), Otsuka Pharmaceutical Co., Ltd. (Japan), Mitotech S.A. (Luxembourg), FCI S.A.S. (France), Shire plc (United States), Sun Pharmaceutical Industries Ltd. (India), Senju Pharmaceutical Co., Ltd. (United States) and TRB Chemedica International SA (Switzerland)


According to AMA, the market for Dry Eye Disease is expected to register a CAGR of 4.35% during the forecast period to 2029. This growth is primarily driven by Rising Customer Awareness about Dry Eye Diseases, Increasing Healthcare expenditure and Up surging Demand of Contact Lenses.

Globally, a noticeable market trend is evident Advance Technology Innovation for Treatment The Diseases & Therapeutic Areas sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Santen Pharmaceutical Co., Ltd. (Japan), Novartis AG (Switzerland), Johnson & Johnson (United States), Valeant Pharmaceuticals International, Inc. (Canada), Allergan plc (Ireland), Otsuka Pharmaceutical Co., Ltd. (Japan), Mitotech S.A. (Luxembourg), FCI S.A.S. (France), Shire plc (United States), Sun Pharmaceutical Industries Ltd. (India), Senju Pharmaceutical Co., Ltd. (United States) and TRB Chemedica International SA (Switzerland), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The dry eye disease market is fragmented in nature due to the presence of many companies operating globally as well as regionally.

Key Developments in the Market:
In July 2023 During the first earnings call Brent Saunders led since his return at Bausch + Lomb, the CEO laid out what he believes is the company’s biggest issue: underutilization of existing infrastructure.
In April 2023 : Sun Pharmaceutical Industries on Tuesday said it has launched a medication to treat dry eye diseases in country.

Influencing Trend:
Advance Technology Innovation for Treatment and Increasing Demand of Treatment Option Such as Lubricant Eye drops, Punctual Bags and Artificial Tears

Market Growth Drivers:
Rising Customer Awareness about Dry Eye Diseases, Increasing Healthcare expenditure and Up surging Demand of Contact Lenses

Challenges:
Increase the humidity in the air at work and at home.

Restraints:
High Price of Drugs and Lack of Skilled Ophthalmologists

Opportunities:
Need to Reduce Cost of Drug and Existence of Untapped Market in the Developing Nations

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Dry Eye Disease Market
- Analysis about New Entrants in Dry Eye Disease Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Dry Eye Disease Study Sheds Light on
— The Dry Eye Disease Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Dry Eye Disease industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Dry Eye Disease industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Artificial Tears
  • Anti-inflammatory Drugs
  • Punctal Plugs
  • Secretagogue
By Application
  • Hospital Pharmacies
  • Independent Pharmacies & Drug Stores
  • Online Pharmacies
By Anti-inflammatory Drugs
  • Cyclosporine
  • Corticosteroids
  • Lifitegrast

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Customer Awareness about Dry Eye Diseases
      • 3.2.2. Increasing Healthcare expenditure
      • 3.2.3. Up surging Demand of Contact Lenses
    • 3.3. Market Challenges
      • 3.3.1. Increase the humidity in the air at work and at home.
    • 3.4. Market Trends
      • 3.4.1. Advance Technology Innovation for Treatment
      • 3.4.2. Increasing Demand of Treatment Option Such as Lubricant Eye drops, Punctual Bags and Artificial Tears
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dry Eye Disease, by Type, Application, Anti-inflammatory Drugs and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Dry Eye Disease (Value)
      • 5.2.1. Global Dry Eye Disease by: Type (Value)
        • 5.2.1.1. Artificial Tears
        • 5.2.1.2. Anti-inflammatory Drugs
        • 5.2.1.3. Punctal Plugs
        • 5.2.1.4. Secretagogue
      • 5.2.2. Global Dry Eye Disease by: Application (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Independent Pharmacies & Drug Stores
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Dry Eye Disease by: Anti-inflammatory Drugs (Value)
        • 5.2.3.1. Cyclosporine
        • 5.2.3.2. Corticosteroids
        • 5.2.3.3. Lifitegrast
      • 5.2.4. Global Dry Eye Disease Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Dry Eye Disease: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Santen Pharmaceutical Co., Ltd. (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Valeant Pharmaceuticals International, Inc. (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Allergan plc (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Otsuka Pharmaceutical Co., Ltd. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mitotech S.A. (Luxembourg)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. FCI S.A.S. (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Shire plc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Senju Pharmaceutical Co., Ltd. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. TRB Chemedica International SA (Switzerland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Dry Eye Disease Sale, by Type, Application, Anti-inflammatory Drugs and Region (value) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Dry Eye Disease (Value)
      • 7.2.1. Global Dry Eye Disease by: Type (Value)
        • 7.2.1.1. Artificial Tears
        • 7.2.1.2. Anti-inflammatory Drugs
        • 7.2.1.3. Punctal Plugs
        • 7.2.1.4. Secretagogue
      • 7.2.2. Global Dry Eye Disease by: Application (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Independent Pharmacies & Drug Stores
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Dry Eye Disease by: Anti-inflammatory Drugs (Value)
        • 7.2.3.1. Cyclosporine
        • 7.2.3.2. Corticosteroids
        • 7.2.3.3. Lifitegrast
      • 7.2.4. Global Dry Eye Disease Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dry Eye Disease: by Type(USD Million)
  • Table 2. Dry Eye Disease Artificial Tears , by Region USD Million (2018-2023)
  • Table 3. Dry Eye Disease Anti-inflammatory Drugs , by Region USD Million (2018-2023)
  • Table 4. Dry Eye Disease Punctal Plugs , by Region USD Million (2018-2023)
  • Table 5. Dry Eye Disease Secretagogue , by Region USD Million (2018-2023)
  • Table 6. Dry Eye Disease: by Application(USD Million)
  • Table 7. Dry Eye Disease Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 8. Dry Eye Disease Independent Pharmacies & Drug Stores , by Region USD Million (2018-2023)
  • Table 9. Dry Eye Disease Online Pharmacies , by Region USD Million (2018-2023)
  • Table 10. Dry Eye Disease: by Anti-inflammatory Drugs(USD Million)
  • Table 11. Dry Eye Disease Cyclosporine , by Region USD Million (2018-2023)
  • Table 12. Dry Eye Disease Corticosteroids , by Region USD Million (2018-2023)
  • Table 13. Dry Eye Disease Lifitegrast , by Region USD Million (2018-2023)
  • Table 14. South America Dry Eye Disease, by Country USD Million (2018-2023)
  • Table 15. South America Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 16. South America Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 17. South America Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 18. Brazil Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 19. Brazil Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 20. Brazil Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 21. Argentina Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 22. Argentina Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 23. Argentina Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 24. Rest of South America Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 27. Asia Pacific Dry Eye Disease, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 31. China Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 32. China Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 33. China Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 34. Japan Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 35. Japan Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 36. Japan Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 37. India Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 38. India Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 39. India Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 40. South Korea Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 41. South Korea Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 42. South Korea Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 43. Taiwan Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 44. Taiwan Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 45. Taiwan Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 46. Australia Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 47. Australia Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 48. Australia Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 52. Europe Dry Eye Disease, by Country USD Million (2018-2023)
  • Table 53. Europe Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 54. Europe Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 55. Europe Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 56. Germany Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 57. Germany Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 58. Germany Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 59. France Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 60. France Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 61. France Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 62. Italy Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 63. Italy Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 64. Italy Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 65. United Kingdom Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 68. Netherlands Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 69. Netherlands Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 70. Netherlands Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 71. Rest of Europe Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 74. MEA Dry Eye Disease, by Country USD Million (2018-2023)
  • Table 75. MEA Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 76. MEA Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 77. MEA Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 78. Middle East Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 79. Middle East Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 80. Middle East Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 81. Africa Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 82. Africa Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 83. Africa Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 84. North America Dry Eye Disease, by Country USD Million (2018-2023)
  • Table 85. North America Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 86. North America Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 87. North America Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 88. United States Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 89. United States Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 90. United States Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 91. Canada Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 92. Canada Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 93. Canada Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 94. Mexico Dry Eye Disease, by Type USD Million (2018-2023)
  • Table 95. Mexico Dry Eye Disease, by Application USD Million (2018-2023)
  • Table 96. Mexico Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2018-2023)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Dry Eye Disease: by Type(USD Million)
  • Table 110. Dry Eye Disease Artificial Tears , by Region USD Million (2024-2029)
  • Table 111. Dry Eye Disease Anti-inflammatory Drugs , by Region USD Million (2024-2029)
  • Table 112. Dry Eye Disease Punctal Plugs , by Region USD Million (2024-2029)
  • Table 113. Dry Eye Disease Secretagogue , by Region USD Million (2024-2029)
  • Table 114. Dry Eye Disease: by Application(USD Million)
  • Table 115. Dry Eye Disease Hospital Pharmacies , by Region USD Million (2024-2029)
  • Table 116. Dry Eye Disease Independent Pharmacies & Drug Stores , by Region USD Million (2024-2029)
  • Table 117. Dry Eye Disease Online Pharmacies , by Region USD Million (2024-2029)
  • Table 118. Dry Eye Disease: by Anti-inflammatory Drugs(USD Million)
  • Table 119. Dry Eye Disease Cyclosporine , by Region USD Million (2024-2029)
  • Table 120. Dry Eye Disease Corticosteroids , by Region USD Million (2024-2029)
  • Table 121. Dry Eye Disease Lifitegrast , by Region USD Million (2024-2029)
  • Table 122. South America Dry Eye Disease, by Country USD Million (2024-2029)
  • Table 123. South America Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 124. South America Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 125. South America Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 126. Brazil Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 127. Brazil Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 128. Brazil Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 129. Argentina Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 130. Argentina Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 131. Argentina Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 132. Rest of South America Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 133. Rest of South America Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 134. Rest of South America Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 135. Asia Pacific Dry Eye Disease, by Country USD Million (2024-2029)
  • Table 136. Asia Pacific Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 137. Asia Pacific Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 138. Asia Pacific Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 139. China Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 140. China Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 141. China Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 142. Japan Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 143. Japan Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 144. Japan Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 145. India Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 146. India Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 147. India Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 148. South Korea Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 149. South Korea Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 150. South Korea Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 151. Taiwan Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 152. Taiwan Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 153. Taiwan Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 154. Australia Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 155. Australia Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 156. Australia Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 157. Rest of Asia-Pacific Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 158. Rest of Asia-Pacific Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 159. Rest of Asia-Pacific Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 160. Europe Dry Eye Disease, by Country USD Million (2024-2029)
  • Table 161. Europe Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 162. Europe Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 163. Europe Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 164. Germany Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 165. Germany Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 166. Germany Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 167. France Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 168. France Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 169. France Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 170. Italy Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 171. Italy Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 172. Italy Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 173. United Kingdom Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 174. United Kingdom Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 175. United Kingdom Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 176. Netherlands Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 177. Netherlands Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 178. Netherlands Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 179. Rest of Europe Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 180. Rest of Europe Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 181. Rest of Europe Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 182. MEA Dry Eye Disease, by Country USD Million (2024-2029)
  • Table 183. MEA Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 184. MEA Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 185. MEA Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 186. Middle East Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 187. Middle East Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 188. Middle East Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 189. Africa Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 190. Africa Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 191. Africa Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 192. North America Dry Eye Disease, by Country USD Million (2024-2029)
  • Table 193. North America Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 194. North America Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 195. North America Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 196. United States Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 197. United States Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 198. United States Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 199. Canada Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 200. Canada Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 201. Canada Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 202. Mexico Dry Eye Disease, by Type USD Million (2024-2029)
  • Table 203. Mexico Dry Eye Disease, by Application USD Million (2024-2029)
  • Table 204. Mexico Dry Eye Disease, by Anti-inflammatory Drugs USD Million (2024-2029)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dry Eye Disease: by Type USD Million (2018-2023)
  • Figure 5. Global Dry Eye Disease: by Application USD Million (2018-2023)
  • Figure 6. Global Dry Eye Disease: by Anti-inflammatory Drugs USD Million (2018-2023)
  • Figure 7. South America Dry Eye Disease Share (%), by Country
  • Figure 8. Asia Pacific Dry Eye Disease Share (%), by Country
  • Figure 9. Europe Dry Eye Disease Share (%), by Country
  • Figure 10. MEA Dry Eye Disease Share (%), by Country
  • Figure 11. North America Dry Eye Disease Share (%), by Country
  • Figure 12. Global Dry Eye Disease share by Players 2023 (%)
  • Figure 13. Global Dry Eye Disease share by Players (Top 3) 2023(%)
  • Figure 14. Global Dry Eye Disease share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Santen Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 17. Santen Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2023
  • Figure 18. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 20. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 21. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 22. Valeant Pharmaceuticals International, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 23. Valeant Pharmaceuticals International, Inc. (Canada) Revenue: by Geography 2023
  • Figure 24. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 25. Allergan plc (Ireland) Revenue: by Geography 2023
  • Figure 26. Otsuka Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 27. Otsuka Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2023
  • Figure 28. Mitotech S.A. (Luxembourg) Revenue, Net Income and Gross profit
  • Figure 29. Mitotech S.A. (Luxembourg) Revenue: by Geography 2023
  • Figure 30. FCI S.A.S. (France) Revenue, Net Income and Gross profit
  • Figure 31. FCI S.A.S. (France) Revenue: by Geography 2023
  • Figure 32. Shire plc (United States) Revenue, Net Income and Gross profit
  • Figure 33. Shire plc (United States) Revenue: by Geography 2023
  • Figure 34. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 35. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2023
  • Figure 36. Senju Pharmaceutical Co., Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Senju Pharmaceutical Co., Ltd. (United States) Revenue: by Geography 2023
  • Figure 38. TRB Chemedica International SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 39. TRB Chemedica International SA (Switzerland) Revenue: by Geography 2023
  • Figure 40. Global Dry Eye Disease: by Type USD Million (2024-2029)
  • Figure 41. Global Dry Eye Disease: by Application USD Million (2024-2029)
  • Figure 42. Global Dry Eye Disease: by Anti-inflammatory Drugs USD Million (2024-2029)
  • Figure 43. South America Dry Eye Disease Share (%), by Country
  • Figure 44. Asia Pacific Dry Eye Disease Share (%), by Country
  • Figure 45. Europe Dry Eye Disease Share (%), by Country
  • Figure 46. MEA Dry Eye Disease Share (%), by Country
  • Figure 47. North America Dry Eye Disease Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Santen Pharmaceutical Co., Ltd. (Japan)
  • Novartis AG (Switzerland)
  • Johnson & Johnson (United States)
  • Valeant Pharmaceuticals International, Inc. (Canada)
  • Allergan plc (Ireland)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Mitotech S.A. (Luxembourg)
  • FCI S.A.S. (France)
  • Shire plc (United States)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Senju Pharmaceutical Co., Ltd. (United States)
  • TRB Chemedica International SA (Switzerland)
Additional players considered in the study are as follows:
Mitotech SA (Luxembourg) , Bausch Health (Canada) , GlaxoSmithKline plc. (United Kingdom) , Auven Therapeutics (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 165 Pages 94 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dry Eye Disease Market Quantitative research analysis
Global Dry Eye Disease Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Dry Eye Disease market are Santen Pharmaceutical Co., Ltd. (Japan), Novartis AG (Switzerland), Johnson & Johnson (United States), Valeant Pharmaceuticals International, Inc. (Canada), Allergan plc (Ireland), Otsuka Pharmaceutical Co., Ltd. (Japan), Mitotech S.A. (Luxembourg), FCI S.A.S. (France), Shire plc (United States), Sun Pharmaceutical Industries Ltd. (India), Senju Pharmaceutical Co., Ltd. (United States) and TRB Chemedica International SA (Switzerland), to name a few.
North America is dominating the Dry Eye Disease Market.
"Increase the humidity in the air at work and at home." is seen as one of the major challenges by many Industry Players of Dry Eye Disease Market
The Dry Eye Disease market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Dry Eye Disease market is expected to see a steady growth rate during projected year 2023 to 2029.

Know More About Global Dry Eye Disease Market Report?

Have a Query? Click Here

Other Related Reports

Hypercalcemia Treatment Comprehensive Study by Application (Mild Hypercalcemia, Moderate Hypercalcemia, Severe Hypercalcemia), Treatment (Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidro...
$ 3650
Postpartum Hemorrhage Comprehensive Study by Type (Early Postpartum Hemorrhage, Late Postpartum Hemorrhage), Application (Hospitals, Clinics, Other), Drugs (Oxytocin, Prostaglandins (Dinoprostone, Mi...
$ 3750
Cancer Therapeutics and Biotherapeutics Comprehensive Study by Type (Chemotherapy, Radiation Therapy, Hormone Therapy, Biotherapy), Application (Household, Hospital, Others), Therapy Type (Monoclonal...
$ 3800
Anti-Aging Products and Therapies Comprehensive Study by Type (Human Growth Hormone, Stem Cell, Placenta, Botulinum Toxin, Hyaluronic Acid), Application (Anti-Pigmentation Therapy, Anti-Cellulite Tre...
$ 3750
Duchenne Muscular Dystrophy Comprehensive Study by Type (Duchenne/Becker (DMD/BMD), Myotonic (DM), Limb-Girdle (LGMD), Facioscapulohumeral (FSHD), Congenital (CMD), Oculopharyngeal (OPMD), Emery-Drei...
$ 3650
Diabetic Neuropathy Comprehensive Study by Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), Application (Hospitals, Clinics, Retail Pharmacy, Online Pharmacy...
$ 3750